#5256 REACTIVATION OF HEPATITIS B VIRUS IN KIDNEY TRANSPLANT RECIPIENTS WITH RESOLVED INFECTION: A SINGLE-CENTER EXPERIENCE

Abstract Background and Aims Patients with end-stage renal disease (ESRD) frequently present serologic evidence of previous contact hepatitis B virus (HBV). Although uncommon, HBV reactivation after kidney transplantation (KT) may cause serious complications adverse outcomes in these patients. However, data regarding risk factors for are still scarce. This study aims to describe a cohort patients resolved infection who showed the KT. Method Retrospective including underwent KT between August 2007 December 2021. Resolved was defined as being seronegative HB surface antigen (HBsAg) seropositive core antibody (HBcAb), regardless (HBsAb) status. seropositivity HBsAg or presence HBV-DNA serum (viraemia). Preemptive prophylactic entecavir not used. Demographic clinical were collected from electronic records. Results A total 104 (70.2% male) included mean age 52±10 years. Prior KT, 93.3% HBsAb. Seropositivity other viruses 18 patients: human immunodeficiency (HIV) alone 5 patients, C (HCV) 11 coinfection 2 Deceased-donor performed 94.2% only 9 had Rituximab used induction immunosuppressive therapy 13 Median follow-up time 75 months (IQR 37-115). occurred 6 median 3-11.5). At diagnosis, titer 83.2 34-784.5; reference range < 1) viral load 6.7 × 106 copies/mL 0.4 106-378 106). Only one patient presented without viraemia. Half HBsAb prior became at diagnosis. No liver enzyme elevation registered Donor HBcAb status, HIV HCV, use recipient status associated Two lost graft function died during follow-up. Conclusion Hepatitis is possible pose major adjustments treatment, namely therapy. Careful monitoring serology viraemia could be particularly useful early diagnosis prompt approach its reactivation. Larger multi-center studies warranted identify specific this population prevent